Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As Pfizer Closes Door On Exubera, Has Window Opened For Others?

Executive Summary

Pfizer's decision to terminate its Exubera program - the first inhaled insulin product to hit the market - could provide an opportunity for other drug makers looking to step into the market, especially those prepared to address obstacles illuminated by Pfizer
Advertisement

Related Content

Ghosts of Exubera Haunt Afrezza As Lung Function, Cancer Concerns Weigh Heavily
NDA Submitted, MannKind’s Inhaled Insulin Faces Next Test: Finding A Partner
Pfizer Reports Lung Cancer Development In Some Exubera Users
Pfizer returns Exubera to Nektar
Avandia Retaining Preferred Status On 2008 Part D Formularies – For Now
Fill It Up: Pfizer To Consider More Flexible Deals, Alliances To Bolster Pipeline
Fill It Up: Pfizer To Consider More Flexible Deals, Alliances To Bolster Pipeline
Lilly Expects Experience To Help Avoid Mistakes Of Pfizer’s Exubera Launch
Lilly Expects Experience To Help Avoid Mistakes Of Pfizer’s Exubera Launch
Pfizer Predicts Exubera, Chantix Favorable Reimbursement Despite Delays
Advertisement
UsernamePublicRestriction

Register

PS048899

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel